Clinical Uses of Membrane Lipid Replacement Supplements in Restoring Membrane Function and Reducing Fatigue in Chronic Diseases and Cancer

Garth L. Nicolson,1,* Steven Rosenblatt2, Gonzalo Ferreira de Mattos3, Robert Settineri4, Paul C. Breeding5, Rita R. Ellithorpe6, Michael E. Ash7

1The Institute for Molecular Medicine, Huntington Beach, California 92647, USA; 2Saint John’s Health Center, Santa Monica, CA, USA; 3Laboratory of Ion Channels, School of Medicine, Universidad de la República, Montevideo, Uruguay, 4Sierra Productions Research, Irvine, CA, USA; 5Blue Hole Wellness, Wimberley, TX, USA; 6Tustin Longevity Center, Tustin, CA, USA; 7Clinical Education, Newton Abbot, Devon, UK.

*Corresponding author: Prof. Emeritus Garth L. Nicolson, PhD, MD (H), Department of Molecular Pathology, The Institute for Molecular Medicine, P.O. Box 9355, S. Laguna Beach, CA 92652; Email: gnicolson@immed.org; Website: www.immed.org

Submitted: February 4, 2016; Revised: February 10; Accepted: February 15, 2016; Published: February 18, 2016; Citation: Nicolson GL, Rosenblatt S, Ferreira de Mattos G, Settineri R, Breeding PC, Ellithorpe RR, Ash ME. Clinical Uses of Membrane Lipid Replacement Supplements in Restoring Membrane Function and Reducing Fatigue in Chronic Diseases and Cancer. Discoveries 2016, January-March; 4(1): e54. DOI: 10.15190/d.2016.1

ABSTRACT
Membrane Lipid Replacement is the use of functional oral supplements containing cell membrane glycerolphospholipids and antioxidants to safely replace damaged membrane lipids that accumulate during aging and in various chronic and acute diseases. Most if not all clinical conditions and aging are characterized by membrane phospholipid oxidative damage, resulting in loss of membrane and cellular function. Clinical trials have shown the benefits of Membrane Lipid Replacement supplements in replenishing damaged membrane lipids and restoring mitochondrial function, resulting in reductions in fatigue in aged subjects and patients with a variety of clinical diagnoses. Recent observations have indicated that Membrane Lipid Replacement can be a useful natural supplement strategy in a variety of conditions: chronic fatigue, such as found in many diseases and disorders; fatiguing illnesses (fibromyalgia and chronic fatigue syndrome); chronic infections (Lyme disease and mycoplasmal infections); cardiovascular diseases; obesity, metabolic syndrome and diabetes; neurodegenerative diseases (Alzheimer’s disease); neurobehavioral diseases (autism spectrum disorders); fertility diseases; chemical contamination (Gulf War illnesses); and cancers (breast, colorectal and other cancers). Membrane Lipid Replacement provides general membrane nutritional support during aging and illness to improve membrane function and overall health without risk of adverse effects.

Keywords: Membrane phospholipids, lipid oxidation, mitochondrial function, fatigue, clinical trials, chronic diseases, chronic infections, chemical contamination, neurodegenerative diseases, neurobehavioral diseases, metabolic diseases, cardiovascular diseases, metabolic syndrome, diabetes, obesity, cancer, fertility, aging;

Abbreviations: Cardiovascular disease (CD); chronic fatigue syndrome (CFS); Federal Drug Administration (FDA, U.S.);
Clinical Uses of Membrane Lipid Replacement Supplements

- Membrane Lipid Replacement can restore and help maintain mitochondrial and other membranes by replacing damaged membrane glycerolphospholipids.
- Damage to membrane glycerolphospholipids occurs in essentially all chronic medical conditions and cancer.
- Clinical trials have shown the benefits of oral Membrane Lipid Replacement in restoring mitochondrial function and reducing symptoms, such as fatigue.
- Oral Membrane Lipid Replacement supplements are safe, effective and convenient.

Introduction: Membrane Lipid Replacement

Membrane Lipid Replacement (MLR) is the oral supplementation of membrane glycerolphospholipids and antioxidants to provide replacement molecules that are damaged during chronic illnesses, cancer and aging. Replacement membrane phospholipids are important for a variety of cellular and tissue functions and for general health. For example, membrane glycerolphospholipids form the matrix for all cellular membranes and provide separation of enzymatic and chemical reactions into discrete cellular compartments and organelles, while also being essential for the function of membrane enzymes. They are also an important energy storage reservoir and provide precursors for bioactive molecules that function in signal transduction and molecular recognition pathways. Thus MLR lipids are considered essential for general health.

Orally ingested phospholipids can be degraded into their constituent parts and absorbed; they can be taken in as intact molecules without degradation, or they can be absorbed as small phospholipid droplets and micelles. When present in excess, most phospholipids in the gastrointestinal system are absorbed undegraded as phospholipid droplets. The process is very efficient—over 90% of phospholipids are absorbed and transported into the blood within six hours. In the blood circulation, they are usually found in carrier molecules, such as lipoproteins, or cell membranes of erythrocytes. Eventually they are delivered to tissues and cells where they are transferred by membrane contact and carrier or transport proteins to various cellular and organelle membranes. Along this pathway, and at their ultimate destination, glycerolphospholipids can be enzymatically modified, for example by substitution of their fatty acid side chains, to reflect the specific compositions of the membranes at their final destination. The process appears to be driven by mass action, so excess intact phospholipids have an advantage in being able to reach their final destination without degradation.

Patients with chronic illnesses as well as aged individuals are often deficient in MLR phospholipids, because dietary sources usually cannot provide enough MLR lipids for maintenance of undamaged cellular membranes, and thus health can suffer. To provide the necessary MLR glycerolphospholipids these lipids or other similar bioactive lipids have been used as therapeutic treatments or as supporting molecules for health maintenance. Dietary lipids, such as essential glycerolphospholipids and fatty acids, are effective oral supplements, because they are successfully and efficiently absorbed in the upper small intestine within hours.

In most if not all acute and chronic illnesses cellular membranes are damaged by oxidative free radicals that are produced mainly by mitochondria. During acute and chronic illnesses the concentrations of free radical reactive oxygen species (ROS), such as superoxide anion radicals, hydroxyl radicals and hydrogen peroxide, and reactive nitrogen species (RNS), primarily
peroxynitrite anion, are dramatically increased. The usual cellular antioxidants that normally neutralize these free radical oxidants are unable to neutralize all of them, and thus damage to cellular components occurs\(^3\). Membrane phospholipids and their unsaturated fatty acids are especially sensitive to oxidative damage by ROS and RNS\(^2\). Thus oral supplementation of membrane lipids as MLR molecules for cellular membranes and other structures has been used to restore cellular membranes\(^1,4,16,17\).

2. Compositions of MLR Lipid Supplements

The lipid compositions of most MLR supplements are not available in detail. However, the lipid composition of one MLR supplement, NTFactor\(^9\), was recently disclosed\(^4\). NTFactor Lipids\(^9\), a mixture of glycerolphospholipids based on mitochondrial lipid composition, contains by weight a diverse mixture of glycerolphospholipids: phosphatidylcholine (PC) 31.6%; phosphatidyl-inositol (PI) 24.9%; phosphatidylethanolamine (PE) 18.9%; phosphatidic acid 13.9%; digalactosyldiacylglycerol 5.9%; phosphatidylglycerol (PG) 2.4%; lysophosphatidylcholine 1.0%; phosphatidylserine (PS) 0.5%; and monoglactosyldiacylglycerol 0.3%. It also contains by weight mainly unsaturated fatty acids: linoleic acid or 18:2\(\Delta 9,12\) (n-6) 58.4%; palmitic acid (16:0) 19.4%; oleic acid or 18:1\(\Delta 9\) (n-9) 9.7%; linolenic acid or 18:3\(\Delta 9,12,15\) (n-3) 5.9%; and stearic acid (18:0) 3.9\(^4\). As in all lipid extracts and from different lots, there may be some minor differences in composition from these figures.

Another MLR supplement, ‘Essential phospholipids,’ has been reported to contain 76% PC, 7% PE, 0.5% PI and other undisclosed lipids\(^1,4,15\). Approximately 70% of its fatty acids are linolenic acid\(^17\).

3. MLR Lipid Supplements are Safe

Extremely high doses of MLR phospholipids have been given to animals and humans with no apparent acute or chronic toxicities (reviewed in \(^2,17\)). For example, in a long-term phase I/II clinical trial using patients with cardiovascular disease, PI was given at doses over 5 g per day with no adverse effects\(^8\). The PI was shown to increase plasma high-density lipoprotein-cholesterol and apolipoprotein A1 levels and reduce triglyceride levels without any evidence of toxicity\(^18\).

The use of relatively high oral doses of replacement membrane lipids has actually improved cardiovascular blood markers. In one study, older subjects (60.7 average age) received over 2 g per day of oral glycerolphospholipids (NTFactor\(^9\)) for over 6 months and showed no adverse effects of the MLR phospholipids. In fact, cardiovascular blood marker levels, such as homocysteine, improved significantly during this period (p<0.001) without any evidence of any adverse effects from the MLR phospholipids\(^9\). In fact, there has been no evidence of any toxicity or adverse events from the long-term use of MLR glycerolphospholipids\(^2,4,11,16,17,19,20\). Therefore, the U.S. Federal Drug Administration (FDA) has classified MLR phospholipids as ‘Generally Recognized as Safe’ or GRAS\(^21\).

4. Development of Various MLR Lipid Supplements

Various oral dietary phospholipid supplements have been developed over the years that contain mixtures of the common membrane glycerolphospholipids and other lipid components\(^2,4,11,16,17\). Of the commercially available oral phospholipid supplements, most are lecithin preparations that lack protection from oxidation and enzymatic destruction\(^2,17\). However, some oral MLR supplements, such as NTFactor\(^9\) and NTFactor Lipids\(^9\), are protected against oxidation and degradation and fulfill the requirements for convenience, efficacy and safety\(^1,4\). The MLR lipids in NTFactor\(^9\) and NTFactor Lipids\(^9\) contain fructooligosaccharides that protect the glycerolphospholipids from oxidation, bile and enzymatic destruction and temperature extremes\(^22\). Daily use of MLR supplements have been found to be safe in amounts of several grams of glycerolphospholipids per day\(^2,4\).

Recently supplements have been developed that contain MLR phospholipids along with additional non-MLR lipid ingredients. For example, some NTFactor lipid-containing supplements also contain probiotic bacteria, various vitamins and minerals and other components (Propax\(^\text{TM}\) with NTFactor\(^9\), Advanced Physician’s Formula\(^\text{TM}\), Healthy Aging\(^\text{TM}\), Pro-Green Energy with NTFactor\(^9\), among others). A specific supplement for mitochondrial support, ATP Fuel\(^2,23\).
contains NTFactor® and also NADH, Coenzyme-Q10, vitamin E, α-ketoglutaric acid, L-carnitine, and other ingredients in order to overcome mitochondrial deficiencies other than damaged membrane phospholipids. Oral MLR products, such as those containing purified phosphatidylserine (PS), are also commercially available.

An intravenous-delivered MLR mixture of glycerolphospholipids (‘Essential’ Phospholipids) has been developed that can deliver high concentrations of MLR phospholipids without the need for protective fructooligosaccharides. However, this product is still susceptible to enzymatic and oxidative damage during storage, and daily intravenous delivery comes with some risk for adverse events, such as infection, blood vessel damage, and other potential problems.

5. Mitochondrial Function and Fatigue

The most common clinical use of MLR supplements is to treat fatigue. Fatigue is the most common complaint of patients seeking general medical care, and it is associated with aging and most if not all chronic medical conditions. Fatigue is considered a complex, multi-dimensional sensation that is not well understood but is perceived to be a loss of overall energy, mental or physical tiredness, a feeling of exhaustion or diminished endurance, and an inability to perform even simple tasks without exertion. Fatigue develops during aging and chronic diseases due to a variety of causes, including loss of mitochondrial function. Indeed, moderate to severe fatigue has been directly related to loss of mitochondrial function and diminished production or leakage of ATP.

Some clinical conditions associated with fatigue are closely related to loss of mitochondrial function. Fatigue in chronic fatigue syndrome (CFS/ME), fibromyalgia, cancer, among other conditions, is clearly related to mitochondrial dysfunction, whereas other disorders are less clearly associated with loss of mitochondrial function. For example, certain mental conditions, such as schizophrenia, bipolar disease, among others, some cancers and other conditions may or may not be associated with mitochondrial dysfunction. Mental and cancer patients are often characterized with moderate to severe depression, and depression is frequently related to mild fatigue states where it shows some physical, cognitive and emotional overlap with fatigue.

Loss of mitochondrial function has been related to oxidative damage to mitochondrial membrane lipids. Inner mitochondrial membrane (MIM) lipid damage increases proton and ion leakiness and lowers trans-membrane potential of the MIM, reducing the production of ATP. The consequence of a loss in ATP production is reduced physical and mental performance, as seen with aging and disease. This is obviously seen in chronic fatigue syndrome patients, as these patients present with evidence of oxidative damage to their DNA and lipids, such as oxidized blood markers and oxidized membrane lipids. These are indicators of excess oxidative stress. Thus patients have sustained, elevated levels of free radical oxidants, such as ROS and RNS, which can result in loss of mitochondrial function as well as changes in cytokine levels that can exert a positive feedback on free radical production.

6. Use of Oral MLR Lipid Supplements to Treat Fatigue

MLR supplements have been used in several clinical studies designed to treat moderate to severe chronic fatigue in patients in order to reduce their fatigue scores (Table 1). Although most of the clinical studies in Table 1 were relatively small (less than 50 participants) and open-label, there were significant outcomes in terms of fatigue reductions. One non-open label exception was a cross-over trial studying the effects of NTFactor® on fatigue in moderately to severely fatigued subjects. In this cross-over trial there was good correspondence between reductions in fatigue and gains in mitochondrial function, as assessed by MIM redox potential. After 8 weeks of MLR with 4 g per day of NTFactor®, mitochondrial function improved significantly, and after 12 weeks of NTFactor® supplementation, mitochondrial function was found to be similar to that found in young healthy adults (26.8% increase, p<0.0001). In this study fatigue was reduced 35.5% (p<0.001) during this period. After 12 weeks of supplement use, subjects were placed on placebo without their knowledge for an additional 12 weeks, and their fatigue and mitochondrial function were measured. After the 12-week placebo period, fatigue and
mitochondrial function were intermediate between the initial starting values and those found after eight or 12 weeks on the supplement. Similar results on the effects of NTFactor on fatigue were found in patients with chronic fatigue syndrome (CFS/ME) and/or fibromyalgia, Gulf War illness and chronic Lyme disease (reductions from 26–43%, Table 1). Analyzed together, these clinical data indicate that MLR can be successfully used to reduce fatigue in patients with different diagnoses and moderate to severe fatigue.

Loss of mitochondrial function is not always exclusively linked to membrane lipid damage. To overcome this problem supplements containing coenzyme Q10, L-carnitine, alpha-lipoic acid, NADH, along with MLR glycerol-phospholipids, have been used as combination mitochondrial supplements. As an example of a combination MLR supplement, ATP Fuel® has been used to treat long-term chronic illness patients with intractable fatigue. The patients in the ATP Fuel® clinical studies had been ill with moderate to severe intractable fatigue for an average of over 17 years, and they had been seen by multiple physicians (>15). In addition, they had taken an average of over 35 supplements or drugs with no effect on their fatigue. These patients responded to the MLR combination supplement, showing significant reductions in fatigue within 6 weeks (p<0.0001). Regression analysis of the fatigue data indicated that the reductions were gradual, consistent, and occurred with a high degree of confidence (R² = 0.960-0.998). Thus, the MLR combination supplement proved to be a safe and effective method to significantly reduce fatigue in patients, even after years of intractable fatigue.

### 7. MLR Oral Lipid Supplements and Cancer

In addition to fatigue in chronic illnesses, fatigue is one of the most common symptoms found in cancer patients. It occurs in the earliest forms of cancer to the most progressed metastatic states. Cancer-associated fatigue is not well understood, but it is thought to be due to a combination of the effects of cancer itself plus the effects of cancer treatments. MLR supplements have been used to treat cancer-associated fatigue and the fatigue and other side effects of cancer therapy. For example, PropaxTM with NTFactor® has been used to reduce some of the adverse effects of cancer therapy, such as chemotherapy-induced fatigue, nausea, vomiting, malaise, diarrhea, headaches and other adverse effects of therapy. In advanced metastatic colon,
Table 2. Suggested Doses, Current and Potential Uses of Oral MLR Supplements

| Use                          | Subjects/patients | Age group | MLR Lipid Supplement | NTFL Dose<sup>a</sup> range (g/day) | Reference       |
|------------------------------|-------------------|-----------|-----------------------|--------------------------------------|-----------------|
| General health               | Aged              | senior    | NTFactor/L<sup>b</sup> | 2-3                                  | Ellithorpe et al. 36 |
| Fatigue                      | Aged              | senior    | NTFactor/L            | 2-3                                  | Agadjanyan et al. 37 |
| Fatigue                      | CFS/ME            | adult/teen| NTFactor/L            | 2-4                                  | Nicolson & Ellithorpe 38 |
| Fatigue                      | CFS/ME            | adult     | ATP Fuel              | 4                                    | Nicolson et al. 23,41 |
| Fatigue                      | Fibromyalgia      | adult     | NTFactor/L            | 3-4                                  | Nicolson & Ellithorpe 38 |
| Weight loss                  | Obesity, fatigue  | adult     | NTFactor              | 1-3                                  | Ellithorpe et al. 39 |
| General health               | Neurodegenerative Dis. | adult  | NTFactor/L            | 3-4                                  | Nicolson et al. 46 |
| CD health                    | CD risk/CD disease | adult | NTFactor/L            | 2-4                                  | Ellithorpe et al. 36 |
| Metabolic health             | MetSyn/diabetes   | adult     | NTFactor/L            | 2-4                                  | Nicolson et al. 47 |
| Metabolic health             | Diabetes          | adult     | ATP Fuel              | 4                                    | Nicolson et al. 23 |
| Neurobehavior                | Autism Spectrum Dis. | child | NTFactor/L            | 1-2                                  | Nicolson et al. 46 |
| Infections                   | Lyme/mycoplasma   | adult     | ATP Fuel              | 4                                    | Nicolson et al. 42 |
| Fertility                    | Fertility Diseases | adult | NTFactor/L            | 2-3                                  | -                |
| Fatigue                      | Cancer            | adult     | NTFactor/L            | 2-3                                  | Nicolson and Conklin 44 |
| Anemia                       | Anemia            | adult     | NTFactor/L            | 1-2                                  | Ellithorpe et al. 36 |
| Injury                       | Spinal injury     | adult     | NTFactor/L            | 1-2                                  | Ellithorpe et al. 36 |
| Autoimmune                   | Rheumatoid arthritis | adult | ATP Fuel              | 4                                    | Nicolson et al. 23 |
| General health               | Pregnancy         | adult     | NTFactor/L            | 1-2                                  | Ellithorpe et al. 36 |
| Chemical detox               | GW Illnesses      | adult     | NTFactor/L            | >4                                   | Nicolson et al. 48 |
| Mental clarity               | Aging             | adult     | NTFactor L            | 1-2                                  | Ellithorpe et al. 49 |

<sup>a</sup>Dose range in grams per day based on weight of NTFactor Lipids<sup>b</sup>

<sup>b</sup>NTFactor<sup>®</sup> or NTFactor Lipids<sup>®

CD – cardiovascular disease; CFS/ME – chronic fatigue syndrome/myalgic encephalomyelitis;

GW – Gulf War; MetSyn – metabolic syndrome;

pancreatic and rectal cancer patients Propax™ with NTFactor<sup>®</sup> reduced the adverse effects of chemotherapy, decreasing significantly episodes of severe fatigue, nausea, diarrhea, constipation, skin changes, insomnia and other effects, as assessed by nurses and by the patients themselves. For example, 81% of the patients on chemotherapy that used Propax™ with NTFactor<sup>®</sup> experienced overall improvements in quality of life parameters. In a subsequent double-blind, placebo-controlled crossover trial containing 36 patients on chemotherapy plus Propax™ there were fewer adverse effects of therapy, resulting in improvements in fatigue, nausea, diarrhea, impaired taste, constipation, insomnia and other quality of life indicators<sup>45</sup>. This indicates that MLR supplements can improve cancer care by reducing adverse complications of treating cancers as well as reducing cancer-associated fatigue<sup>3</sup>.

8. Other Clinical Uses of Oral MLR Supplements

MLR lipid supplements have been used in a variety of clinical disorders (Table 2). For example, MLR may modify the metabolism through body mass reduction and appetite restraint<sup>49</sup>. In this study 30 obese but otherwise normal subjects took oral HealthyCurb<sup>®</sup>, a NTFactor<sup>®</sup> and alpha-amylase inhibitor formulation, 30 min before each meal. Over time subjects gradually lost weight, as shown by significant reductions in weight and waist and hip circumferences. They also showed reductions in body mass index (BMI) and basal metabolic rate (BMR) (p<0.001). Overall hunger was reduced during the trial by 44.5% (p<0.001), with decreased cravings for sweets and fats. There was also a 23.9% reduction in fatigue (p<0.009). Along with fatigue reduction, subjects had a 26.8% enhancement in perceived improvements in
cognition and increased abilities to concentrate, remember and think clearly (p<0.004)\(^9\).

Improvements in mental clarity while on MLR lipid supplements have been examined in a preliminary study using NTFactor Lipids\(^9\). A group of 29 subjects were given 0.6 g of NTFactor Lipids\(^6\) in a drink, and fatigue and mental focus were surveyed after three hours. At this time a self-reported survey instrument was given to the participants. A majority of the participants responded within one hour, and by three hours they reported improvements in cognition, mental clarity and focus along with reductions in perceived fatigue\(^9\).

Instead of combinations of glycerophospholipids, specific single glycerophospholipids, such as oral PS, have been used in clinical studies to assess improvements in memory and cognition. In such a study 30 male and female subjects aged 50-90 years were enrolled with memory impairments unrelated to neurological disease, stroke, diabetes, infections or inflammatory processes. After 12-weeks on 300 mg oral PS per day the outcomes in six different tests of memory and cognition were determined\(^9\). At the end of the trial participants showed significant improvements in memory recognition (p=0.004) and recall (p=0.006), total learning (p=0.013), executive functions (p=0.004), metal flexibility, and visual spatial learning. There were no adverse events during the trial, and interestingly both mean systolic and diastolic blood pressure values were reduced at 12 weeks in comparison with baseline values\(^80\). A similar double-blind, randomized clinical trial on 78 subjects (50-69 years old) was conducted to determine if 100-300 mg oral PS per day versus placebo improved memory scores. In this study, PS significantly improved behavioral memory functions, especially short-term memory and cognitive function in low-scoring (delayed word recall) participants (p<0.01)\(^51\).

MLR lipid preparations have been used to treat memory loss in aged subjects and in Alzheimer’s disease (AD)\(^50,52\). AD patients were supplemented with 300 mg per day PS for 6 months. At the end of this period participants showed cognitive improvements relative to placebo controls\(^52\). This result, however, was not found in another study on elderly subjects with age-associated memory impairment that received 300-600 mg soy PS daily for 12 weeks\(^25\).

9. Final Comments

Oral MLR lipid formulations have proven to be safe and effective as daily supplements for replacing damaged membrane glycerolphospholipids and restoring membrane function. That replacing damaged membrane phospholipids has a positive effect on cellular function and health, such as mitochondrial function, has been demonstrated in clinical trials. The positive effects of MLR lipids are also apparent in other membrane compartments, such as the plasma membrane, and additional studies will undoubtedly concentrate on the functional effects of MLR lipids on the plasma membranes of various cell types. Since MLR natural lipid supplements are not drugs, the usual drug safety issues do not apply, as extremely high doses of MLR glycerolphospholipids have been given to animals and humans over long periods of time without any evidence of toxic or adverse effects\(^2\).

It should be clear that additional clinical studies are needed, especially controlled clinical trials, to further examine the role of MLR lipid supplements in improving health and reducing symptoms like fatigue. Important future development will likely center on the neurological aspects of aging and illnesses, such as mood, cognition, executive function, mental flexibility and learning. Also, the long-term use of MLR lipid supplements to enhance cardiovascular health will be another important area of research.

The daily use of MLR lipid supplements to improve health during aging and support the treatment regimens for various clinical conditions is completely justified because of their efficacy and safety. New formulations of MLR lipids and combination MLR supplements are being developed, and these will eventually allow the lipid replacement and repair of vital cellular membranes and other cellular structures that are damaged during aging and illness.

Acknowledgements

This contribution was supported by grants and contracts to the Institute for Molecular Medicine, a non-profit, tax-exempt 501(c)(3) research organization.

Conflict of Interest

Garth Nicolson and Robert Settineri are part-time consultants to Nutritional Therapeutics, Inc. of...
Clinical Uses of Membrane Lipid Replacement Supplements

Hauppaue, NY; Researched Nutritional of Los Olivos, CA; Allergy Research Group of Alameda, CA; and Naturally Plus USA of LasVegas, NV. Settineri is also a consultant to Advanced Biocatalytics of Irvine, CA. Steven Rosenblatt and Gonzalo Ferreira de Mattos have no conflicts to report. Rita Ellithorpe is a part-time consultant to Nutritional Therapeutics, Inc. of Hauppauge, NY; and Researched Nutritional of Los Olivos, CA; Michael Ash is a part-time consultant to Allergy Research Group of Alameda, CA.

References
1. Nicolson GL. Lipid replacement as an adjunct therapy in chronic fatigue, anti-aging and restoration of mitochondrial function. J. Am. Nutraceut. Assoc. 2003; 6(3): 22-28.
2. Nicolson GL, Ash ME. Lipid Replacement Therapy: a natural medicine approach to replacing damaged lipids in cellular membranes and organelles and restoring function. Biochim, Biophys. Acta 2014; 1838: 1657-1679.
3. Nicolson GL. Lipid replacement therapy: a nutraceutical approach for reducing cancer-associated fatigue and the adverse effects of cancer therapy while restoring mitochondrial function. Cancer Metastasis Rev. 2010; 29(3), 543-552.
4. Nicolson GL. Membrane Lipid Replacement: clinical studies using a natural medicine approach to restoring membrane function and improving health. Intern. J. Clin. Med. 2016; 7: in press.
5. Küllenber D, Taylor LA, Schneider M, Massing U. Health effects of dietary phospholipids. Lipids Health Dis. 2012; 11: e3.
6. van Meer G, Voelker DB, Feigenson GW. Membrane lipids: where they are and how they behave. Nat. Rev. Mol. Cell Biol. 2008; 9: 112-124.
7. Escribá PV. Membrane-lipid therapy: a new approach in molecular medicine. Trends Mol. Med. 2006; 12, 34-43.
8. Ibarguren M, López DJ, Escribá PV. The effect of natural and synthetic fatty acids on membrane structure, microdomain organization, cellular functions and human health. Biochim. Biophys. Acta 2014; 1838: 1518-1528.
9. Dobbins WO III. Morphologic aspects of lipid absorption. Am. J. Clin. Nutr. 1969; 22: 257-265.
10. Zierenberg O, Grundy SM. Intestinal absorption of polyenephatidylcholine in man. J. Lipid Res. 1982; 23: 1136-1142.
11. Gundermann KJ, Kuenker A, Kuntz E, Drozdzik M. Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol. Rep. 2011; 63: 643-659.
12. Le Kim D, Betzing H. Intestinal absorption of polyunsaturated phosphatidylcholine in the rat. Hoppe Seylers Zeit. Physiol. Chem. 1976; 357: 1321-1331.
13. Liao TH, Hamosh P, Hamosh M. Fat digestion by lingual lipase: mechanism of lipolysis in the stomach and upper small intestine. Pediatric Res. 1984; 18: 402-409.
14. Adibhatla RM, Hatcher JF. Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signal. 2010; 12: 125-169.
15. Catalá A. Lipid peroxidation modifies the picture of membranes from the “Fluid Mosaic Model” to the “Lipid Whisker Model.” Biochimie 2012; 94: 101-109.
16. Wagener HH, Fontaine R, Neumann B. Pharmakologie “essentiele” phospholipide (EPL). Drug Res. 1976; 26: 1733-1743.
17. Gundermann KJ. The “essential” phospholipids as membrane therapeutic. European Society of Biochemical Pharmacology, 1993, Szczecin, Poland.
18. Pandey NR, Sparks DL. Phospholipids as cardiovascular therapeutics. Curr. Opin. Invest. Drugs 2008; 9(3), 281-285.
19. Ellithorpe RR, Settineri R, Ellithorpe T, Nicolson GL. Blood homocysteine and fasting insulin levels are reduced and erythrocyte sedimentation rates are increased with a glycopospholipid-vitamin formulation: a retrospective study in older subjects. Funct. Foods Health Dis. 2015; 5(4): 126-135.
20. Cohn JS, Wat E, Kamili A, Tandy S. Dietary phospholipids, hepatic metabolism and cardiovascular disease. Curr. Opin. Lipidol. 2008; 19: 257-262.
21. U. S. Federal Drug Administration. Scientific literature reviews on generally recognized as safe (GRAS) food ingredients: Lecithins. GRAS Report, 1970; PB-241 970.
22. Hendry GAF. Evolutionary origins and natural functions of fructans—a climatological, biogeographic and mechanistic appraisal. New Phytol. 1993; 123: 3-14.
23. Nicolson GL, Settineri R, Ellithorpe R. Lipid Replacement Therapy with a glycopospholipid formulation with NADH and CoQ10 significantly reduces fatigue in intractable chronic fatigue illness and chronic Lyme disease. Intern. J. Clin. Med. 2012; 3: 163-170.
24. Nicolson GL. Mitochondrial dysfunction and chronic disease: treatment with natural
Clinical Uses of Membrane Lipid Replacement Supplements

supplements. *Altern. Ther. Health Med.* 2014; 20(Suppl 1): 18-25.

25. Jorissen BL, Brouns F, van Boxtel MP, Ponds RW, Verhey FR, Jolles J, Riedel WJ. The influence of soy-derived phosphatidylserine on cognition in age-associated memory impairment. *Nutr. Neurosci.* 2001; 4: 121-134.

26. Morrison JD. Fatigue as a presenting complaint in family practice. *J. Family Pract.* 1980; 10: 795-801.

27. Kroenke K, Wood DR, Mangelsdorff AD, Meier NJ, Powell JB. Chronic fatigue in primary care. Prevalence, patient characteristics, and outcome. *JAMA* 1988; 260: 929-934.

28. Filler K, Lyon D, Bennett J, McCain N, Elswick R, Lukkahatai N, Saligan LN. Association of mitochondrial dysfunction and fatigue: a review of the literature. *BBA Clin.* 2014; 1: 12-23.

29. Krupp LB, Pollina DA. Mechanisms and management of fatigue in progressive neurological disorders. *Curr. Opin. Neurol.* 1996; 9: 456-460.

30. Myhill S, Booth NE, McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. *Intern. J. Clin. Expl. Med.* 2009; 2: 1-16.

31. Brown LF, Kroenke K. Cancer-associated fatigue and its association with depression and anxiety: a systematic review. *Psychosomat.* 2009; 50: 440-447.

32. Manuel y Keenoy B, Moorkens G, Vertommen J, De Leeuw I. Antioxidant status and lipoprotein peroxidation in chronic fatigue syndrome. *Life Sci.* 2001; 68: 2037-2049.

33. Fulle S, Meccoli P, Fano G, Vecchiet I, Racciotti D, Cherubini A, Pizzigallo E, Vecchiet L, Senin U, Beal MF. Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. *Free Rad. Biol. Med.* 2000; 29: 1252-1259.

34. Pall ML. Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. *Med. Hypoth.* 2000; 54: 115-125.

35. Richards RS, Roberts TK, McGregor NR, Dunstan RH, Butt HL. Blood parameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome. *Redox Rep.* 2000; 5: 35-41.

36. Ellithorpe RR, Settineri R, Nicolson GL. Reduction of fatigue by use of a dietary supplement containing glycophospholipids. *J. Am. Nutraceut. Assoc.* 2003; 6(1): 23-28.

37. Agadjanyan M, Vasilevko V, Ghochikyan A, Berns P, Kesslak P, Settineri R, Nicolson GL. Nutritional supplement (NTFactor) restores mitochondrial function and reduces moderately severe fatigue in aged subjects. *J. Chronic Fatigue Syndr.* 2003; 11(3): 23-36.

38. Nicolson GL, Ellithorpe R. Lipid replacement and antioxidant nutritional therapy for restoring mitochondrial function and reducing fatigue in chronic fatigue syndrome and other fatiguing illnesses. *J. Chronic Fatigue Syndr.* 2006; 13(1), 57-68.

39. Ellithorpe RA, Settineri R, Jacques B, Nicolson GL. Lipid Replacement Therapy functional food with NTFactor for reducing weight, girth, body mass, appetite, cravings for foods and fatigue while improving blood lipid profiles. *Funct. Foods Health Dis.* 2012; 2(1): 11-24.

40. Nicolson GL, Ellithorpe RR, Ayson-Mitchell C, Jacques B, Settineri R. Lipid Replacement Therapy with a glycophospholipid-antioxidant-vitamin formulation significantly reduces fatigue within one week. *J. Am. Nutraceut. Assoc.* 2010; 13(1): 11-15.

41. Nicolson GL, Settineri R, Ellithorpe RR. Lipid Replacement Therapy with a glycophospholipid formulation containing NADH and CoQ10 significantly reduces fatigue and improves mood and cognition in intractable chronic fatigue illnesses and chronic Lyme disease. *Townsend Lett.* 2012; 347(6): 58-61.

42. Nicolson GL, Settineri R, Ellithorpe RR. Glycophospholipid formulation with NADH and CoQ10 significantly reduces fatigue in Western blot-positive chronic Lyme disease patients: preliminary report. *Funct. Foods Health Dis.* 2012; 2(3): 35-47.

43. Piper BF, Linsey AM, Dodd MJ. Fatigue mechanism in cancer. *Oncol. Nurs. Forum* 1987; 14:17-23.

44. Nicolson GL, Conklin KA. Reversing mitochondrial dysfunction, fatigue and the adverse effects of chemotherapy of metastatic disease by Molecular Replacement Therapy. *Clin. Exp. Metastasis* 2008; 25: 161-169.

45. Colodny L, Lynch K, Farber C, Papish R, Phillips K, Sanchez M, Cooper K, Pickus O, Palmer D, Percy TB, Faroqui M, Block JB. Results of a study to evaluate the use of Propax to reduce adverse effects of chemotherapy. *J. Am. Nutraceut. Assoc.* 2001; 3(1): 17-25.

46. Nicolson GL, Settineri R, Ellithorpe RR. Neurodegenerative and fatiguing illnesses, infections and mitochondrial dysfunction: the use of natural supplements to improve mitochondrial function. *Funct. Foods Health Dis.* 2014; 4(1): 23-65.

47. Nicolson GL. Metabolic syndrome and mitochondrial function: molecular replacement and antioxidant supplements to prevent
membrane oxidation and restore mitochondrial function. *J. Cell. Biochem.* 2007; 100: 1352-1369.

48. Nicolson GL, Berns P, Nasralla M, Haier J, Nicolson NL, Nass M. Gulf War Illnesses: chemical, radiological and biological exposures resulting in chronic fatiguing illnesses can be identified and treated. *J. Chronic Fatigue Syndr.* 2003; 11(1): 135-154.

49. Ellithorpe RR, Settineri R, Mitchell CA, Jacques B, Ellithorpe T, Nicolson GL. Lipid replacement therapy drink containing a glycopropholipid formulation rapidly and significantly reduces fatigue while improving energy and mental clarity. *Funct. Foods Health Dis.* 2011; 1(8): 245-254.

50. Richter Y, Herzog Y, Lifshitz Y, Hayun R, Zchut S. The effect of soybean phosphatidylserine on cognitive performance in elderly with subjective memory complaints: a pilot study. *Clin. Intervent. Aging* 2013; 8: 557-563.

51. Kato-Kataoka A, Sukai M, Ebina R, Nonaka C, Asano T, Miyamori T. Soybean-derived phosphatidyserine improves memory function of elderly Japanese subjects with memory complaints. *J. Clin. Biochem. Nutr.* 2010; 47: 246-255.

52. Cernacchi T, Bertoldin T, Farina C, Flori MG, Crepaldi G. Cognitive decline in the elderly: a double-blind, placebo-controlled multicenter study on the efficacy of phosphatidylserine administration. *Aging (Milano)* 1993; 5: 123-133.

DISCOVERIES is a peer-reviewed, open access, online, multidisciplinary and integrative journal, publishing high impact and innovative articles from all areas related to Medicine, Biology and Chemistry; © 2016, Applied Systems